UroGen Pharma Ltd. (URGN)
Automate Your Wheel Strategy on URGN
With Tiblio's Option Bot, you can configure your own wheel strategy including URGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol URGN
- Rev/Share 1.9373
- Book/Share -0.9797
- PB -13.5148
- Debt/Equity -2.6895
- CurrentRatio 5.6471
- ROIC -0.5343
- MktCap 610463300.0
- FreeCF/Share -2.2646
- PFCF -5.6843
- PE -4.5356
- Debt/Assets 0.5046
- DivYield 0
- ROE -974.8662
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | URGN | H.C. Wainwright | Neutral | Buy | -- | $50 | June 16, 2025 |
| Downgrade | URGN | H.C. Wainwright | Buy | Neutral | -- | -- | May 22, 2025 |
| Initiation | URGN | Scotiabank | -- | Sector Outperform | -- | $23 | April 16, 2025 |
| Resumed | URGN | Ladenburg Thalmann | -- | Buy | -- | $31 | Feb. 19, 2025 |
| Initiation | URGN | Guggenheim | -- | Buy | -- | $40 | Aug. 22, 2024 |
News
URGN INVESTOR ALERT: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: May 29, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , May 29, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the "Class Period"), have until July 28, 2025 to seek appointment as lead plaintiff of the UroGen class action lawsuit.
Read More
Did You Suffer Losses in UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About Securities Fraud Claims
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman
Published: May 29, 2025 by: PRNewsWire
Sentiment: Neutral
URGN Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , May 29, 2025 /PRNewswire/ -- On May 21, 2025, investors in UroGen Pharma Ltd. (NASDAQ: URGN) saw the price of their shares crash 44% after the company announced that the FDA's Oncologic Drugs Advisory Committee ("ODAC") voted against the risk/benefit profile of UroGen's UGN-102, a therapy intended to treat patients with low-grade, intermediate-risk non-muscle invasive bladder cancer ("LG-IR-NMIBC") for which no drugs are currently FDA-approved.
Read More
Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About Fraud Investigation
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ:URGN).
Read More
Levi & Korsinsky Investigating Whether UroGen Pharma Ltd. (URGN) Misled Investors - Securities Law Violations Possible
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating UroGen Pharma Ltd. (URGN) And Encourages Investors to Connect
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ:URGN).
Read More
Did UroGen Pharma Ltd. (URGN) Mislead Investors?
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
Investigation Alert: UroGen Pharma Ltd. (URGN) Under Scrutiny - Contact Levi & Korsinsky for Details
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny – Hagens Berman
Published: May 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- On May 21, 2025, investors in UroGen Pharma Ltd. (NASDAQ: URGN) saw the price of their shares crash 44% after the company announced that the FDA's Oncologic Drugs Advisory Committee (“ODAC”) voted against the risk/benefit profile of UroGen's UGN-102, a therapy intended to treat patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (“LG-IR-NMIBC”) for which no drugs are currently FDA-approved.
Read More
Did You Suffer Losses in UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About Securities Fraud Claims
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ:URGN).
Read More
Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky to Protect Your Rights
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages UroGen Pharma Ltd. (URGN) Stockholders to Inquire about Securities Investigation
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ:URGN).
Read More
ATTENTION UroGen Pharma Ltd. (URGN) Investors: Possible Fraud - Contact Levi & Korsinsky Today
Published: May 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug
Published: May 25, 2025 by: Benzinga
Sentiment: Negative
HC Wainwright & Co. analyst Raghuram Selvaraju downgraded the rating on UroGen Pharma Ltd. URGN from Buy to Neutral.
Read More
Ongoing Securities Investigation into UroGen Pharma Ltd. (URGN) - Contact Levi & Korsinsky
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral
URGN Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, CA / ACCESS Newswire / May 23, 2025 / On May 21, 2025, investors in UroGen Pharma Ltd. (NASDAQ:URGN)saw the price of their shares crash 44% after the company announced that the FDA's Oncologic Drugs Advisory Committee ("ODAC") voted against the risk/benefit profile of UroGen's UGN-102, a therapy intended to treat patients with low-grade, intermediate-risk non-muscle invasive bladder cancer ("LG-IR-NMIBC") for which no drugs are currently FDA-approved.
Read More
Potential Securities Fraud: Levi & Korsinsky Investigates UroGen Pharma Ltd. (URGN)
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Published: May 23, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ:URGN).
Read More
URGN ACTIVE INVESTIGATION: Lost Money on UroGen Pharma Ltd.? Contact Levi & Korsinsky Now
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny – Hagens Berman
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, May 22, 2025 (GLOBE NEWSWIRE) -- On May 21, 2025, investors in UroGen Pharma Ltd. (NASDAQ: URGN) saw the price of their shares crash 44% after the company announced that the FDA's Oncologic Drugs Advisory Committee (“ODAC”) voted against the risk/benefit profile of UroGen's UGN-102, a therapy intended to treat patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (“LG-IR-NMIBC”) for which no drugs are currently FDA-approved.
Read More
Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About Investigation
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Stockholders to Learn More About the Investigation
Published: May 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ:URGN).
Read More
UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, Either
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Positive
UroGen Pharma Ltd.'s investment thesis hinges on FDA approval of UGN-102, a minimally invasive bladder cancer treatment with a June 13 decision date. ODAC narrowly voted against approval, citing insufficient comparative data, but a split panel and urologist support leave room for a positive FDA surprise. URGN faces significant financial risk, with only 4-5 quarters of cash and inability to fund another confirmatory trial if required by the FDA.
Read More
Ongoing Investigation: UroGen Pharma Ltd. (URGN) May Have Misled Shareholders - Levi & Korsinsky Investigates
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages UroGen Pharma Ltd. (URGN) Investors to Inquire about Securities Investigation
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UroGen Pharma Ltd. ("UroGen" or "the Company") (NASDAQ:URGN).
Read More
Ongoing Securities Investigation into UroGen Pharma Ltd. (URGN) - Contact Levi & Korsinsky
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ:URGN).
Read More
Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky to Protect Your Rights
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.
Read More
About UroGen Pharma Ltd. (URGN)
- IPO Date 2017-05-04
- Website https://www.urogen.com
- Industry Biotechnology
- CEO Ms. Elizabeth A. Barrett
- Employees 234